Risks for JOHNSON & JOHNSON (JNJ)

Here are some interesting risks from the recent filings of JOHNSON & JOHNSON. Our algorithms work hard to highlight risks unique to this company.

(infliximab), is experiencing biosimilar competition, which will result in a reduction in U.S. sales of REMICADE

The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.

The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.

Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.

The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.